Table 2. Hemodynamics pre- and post-therapy.
| Clinical parameter | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 | Patient 9 | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre | Post | Pre | Post | Pre | Post | Pre | Post | Pre | Post | Pre | Post | Pre | Post | Pre | Post | Pre | Post | |||||||||
| NT-proBNP | 10,067 | 28,910 | – | 99 | 833 | 3,977 | 1,331 | 4,071 | 2,973 | 2,018 | – | – | 2,369 | 123 | 199 | 151 | 442 | 1,063 | ||||||||
| WHO FC | 3 | 3 | 4 | 4 | 4 | 3 | 3 | 3 | 4 | 4 | 4 | – | 3 | 4 | 4 | 4 | 4 | 4 | ||||||||
| RAP | 24 | – | 7 | 9 | 6 | – | 11 | – | 18 | 4 | 14 | – | 5 | – | 17 | 6 | 12 | 10 | ||||||||
| mPAP | 77 | – | 62 | 52 | 45 | – | 51 | – | 32 | 34 | 59 | – | 57 | – | 69 | 42 | 66 | 50 | ||||||||
| CI | 2.1 | – | 2.4 | 3 | 2.5 | – | 2.3 | – | 1.6 | 2.3 | 1.7 | – | 1.6 | – | 1.5 | 4.5 | 1.8 | 4 | ||||||||
| PVR | 14 | – | 16 | 10 | 7 | – | 9 | – | 10 | 8 | 17 | – | 18 | – | 21 | 4 | 16.3 | 5.2 | ||||||||
| *RVSP | 151 | 133 | 110 | 94 | 98 | 67 | 87 | 111 | 54 | 82 | 66 | – | 99 | – | 90 | 104 | 91 | 59 | ||||||||
| Parenteral prostanoid and dose at 1 year (ng/kg/min) | IV Epo, 13 | IV Tre, 84 | SC Tre, 15.5 | IV Epo, 21 | IV Tre, 42 | IV Epo, 10 | IV Epo, 7 | IV Epo, 35 | SC Tre, 22 | |||||||||||||||||
| Survival free from transplant (days) | 78 | 1,554 | 432 | 384 | 2,221 | 23 | 97 | 609 | 673 | |||||||||||||||||
Parenteral prostanoid dose at 1 year, or last follow-up for those treated for <1 year. *, Median time to first follow-up echocardiogram was 350 days (IQR: 330). NT-proBNP, N-terminal prohormone of brain natriuretic peptide; WHO FC, World Health Organization Functional Class; RAP, right atrial pressure; mPAP, mean pulmonary artery pressure; CI, cardiac index; PVR, pulmonary vascular resistance; RVSP, right ventricular systolic pressure; IV, intravenous; Epo, epoprostenol; Tre, Treprostinil; SC, subcutaneous; IQR, interquartile range.